Unraveling tumor–immune heterogeneity in advanced ovarian cancer uncovers immunogenic effect of chemotherapy

June 1, 2020

In this study we demonstrate that the tumour–immune microenvironment (TME) of advanced high-grade serous ovarian cancer (HGSOC) is intrinsically heterogeneous and that chemotherapy induces local immune activation. Therefore, exploring new combination therapies and therapeutic targets based on a greater understanding of the TME has the potential to change the current treatment paradigm and improve clinical outcomes in patients with HGSOC.

 

Unraveling tumor–immune heterogeneity in advanced ovarian cancer uncovers immunogenic effect of chemotherapy
Connect

Connect with us

The Mark Foundation Institute for Integrated Cancer Medicine (MFICM) at the University of Cambridge aims to revolutionise cancer care by affecting patients along their treatment pathway.

Find out more

Connect